Stock Analysis
M&Z (MTSE:MZ) Full Year 2023 Results
Key Financial Results
- Revenue: €31.3m (up 10% from FY 2022).
- Net income: €1.77m (up 31% from FY 2022).
- Profit margin: 5.6% (up from 4.8% in FY 2022). The increase in margin was driven by higher revenue.
- EPS: €0.04 (up from €0.031 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
M&Z's share price is broadly unchanged from a week ago.
Risk Analysis
Be aware that M&Z is showing 4 warning signs in our investment analysis and 2 of those don't sit too well with us...
Valuation is complex, but we're helping make it simple.
Find out whether M&Z is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About MTSE:MZ
M&Z
Engages in the importation, marketing, and distribution of fast-moving consumer goods and pharmaceutical non-medical products.
Excellent balance sheet with proven track record.